Pasithea is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).
Company profile
Ticker
KTTA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Alpha 5 Integrin, LLC • AlloMek Therapeutics, LLC ...
IRS number
851591963
KTTA stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
3 Apr 24
S-8
Registration of securities for employees
29 Mar 24
POS AM
Prospectus update (post-effective amendment)
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
18 Jan 24
8-K
Material Modifications to Rights of Security Holders
2 Jan 24
DEFA14A
Additional proxy soliciting materials
28 Dec 23
8-K
Material Modifications to Rights of Security Holders
28 Dec 23
DEFA14A
Additional proxy soliciting materials
19 Dec 23
8-K
Departure of Directors or Certain Officers
19 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.58 mm | 19.58 mm | 19.58 mm | 19.58 mm | 19.58 mm | 19.58 mm |
Cash burn (monthly) | 2.35 mm | 1.90 mm | 1.26 mm | 1.43 mm | 43.15 k | 297.28 k |
Cash used (since last report) | 16.07 mm | 12.97 mm | 8.62 mm | 9.76 mm | 294.50 k | 2.03 mm |
Cash remaining | 3.52 mm | 6.62 mm | 10.96 mm | 9.83 mm | 19.29 mm | 17.56 mm |
Runway (months of cash) | 1.5 | 3.5 | 8.7 | 6.9 | 447.1 | 59.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 167.48 mm |
Total shares | 7.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Paul B Manning | 3.41 mm | $3.30 mm |
Armistice Capital | 1.00 mm | $15.80 mm |
IOI Ionic Ventures | 870.27 k | $1.54 mm |
Alpha Capital Anstalt | 715.00 k | $1.27 mm |
Kepos Capital | 334.60 k | $5.00 k |
Warberg Asset Management | 289.97 k | $6.23 mm |
Vanguard | 121.01 k | $59.29 mm |
Geode Capital Management | 98.25 k | $48.14 mm |
HRT Financial | 41.13 k | $20.00 k |
Renaissance Technologies | 34.73 k | $17.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Lawrence Steinman | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 7,500 | 62.55 k | 7,500 |
1 Mar 24 | Schneiderman Daniel H | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 5,927 | 49.43 k | 5,927 |
1 Mar 24 | Schneiderman Daniel H | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 10,000 | 83.40 k | 10,000 |
1 Mar 24 | Novak Alfred J | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 5,000 | 41.70 k | 5,000 |
1 Mar 24 | Tiago Marques | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 11,669 | 97.32 k | 11,669 |
1 Mar 24 | Tiago Marques | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 15,000 | 125.10 k | 15,000 |
1 Mar 24 | Emer Leahy | Stock Option Common Stock | Grant | Acquire A | No | No | 8.34 | 7,500 | 62.55 k | 7,500 |